Plain-English translation of NCT07615348 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach for patients with advanced clear cell kidney cancer who have early or intermediate risk disease. You would first receive standard combination therapy (an immune checkpoint inhibitor plus a targeted drug) for 12 months. Then, if your cancer responds well and special imaging shows no active disease, you would take a break from all treatment while doctors monitor you closely.
Current kidney cancer treatment is very effective but requires taking medication continuously, which can cause side effects, become expensive, and may treat patients longer than necessary. This trial is exploring whether a treatment break is safe for patients whose cancer has responded well, potentially reducing toxicity and burden while maintaining cancer control.
You likely qualify if…
You likely don't qualify if…
You would receive combination therapy (two medications given together) for 12 months. After 12 months, if your cancer has responded well on standard imaging and a special molecular imaging scan shows no active disease, you would stop all treatment and enter a monitoring phase. During the monitoring phase, you would have CT scans every 8-12 weeks and special imaging scans every 24 weeks, along with blood tests, to watch for any signs of the cancer returning.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China